Professor, Medicine, University of Washington School of Medicine
Internal Medicine
Dr. David C. Dale, MD
|
|
Give Review
Doctor David C. Dale, MD is an expert in the field of Internal Medicine. He graduated from Harvard Medical School. Harvard Medical School is a top medical university. Harvard Medical School is ranked 1/12 in Research/PrimaryCare. He has 1 awards "Elected Member". David C. Dale is a published physician. He published 82 publications, including: 'How I diagnose and treat neutropenia.' He is registered with Medicare.
Publications
- How I diagnose and treat neutropenia.
- Assessing patients' risk of febrile neutropenia: is there a correlation between physician-assessed risk and model-predicted risk?
- Use of granulocyte colony-stimulating factor during pregnancy in women with chronic neutropenia.
- The diversity of mutations and clinical outcomes for ELANE-associated neutropenia.
- Understanding, Treating and Avoiding Hematological Disease: Better Medicine Through Mathematics?
- Cancer Chemotherapy Treatment Patterns and Febrile Neutropenia in the US Veterans Health Administration.
- TCIRG1-Associated Congenital Neutropenia.
- Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study.
- Variable Clinical Presentation of Shwachman-Diamond Syndrome: Update from the North American Shwachman-Diamond Syndrome Registry.
- Understanding neutropenia.
- Risk factors for in-hospital mortality and prolonged length of stay in older patients with solid tumor malignancies.
- Evaluation and management of patients with isolated neutropenia.
- Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer.
- Improving care of patients with immunodeficiency diseases.
- Repeated Lentivirus-mediated G-CSF Administration to Treat Canine Cyclic Neutropenia.
- Do G-CSF Schedules Make a Difference?
- Guidelines for pediatric management of severe chronic neutropenia.
- Twenty years of the colony-stimulating factors.
- Cyclic and chronic neutropenia: an update on diagnosis and treatment.
- The Cellular and Molecular Mechanisms for Neutropenia in Barth Syndrome.
- Comparison of Demographic Characteristics, Surgical Resection Patterns, and Survival Outcomes for Veterans and Nonveterans with Non-small Cell Lung Cancer in the Pacif...
- The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome.
- Long-term outcomes of myeloid growth factor treatment.
- Editorial: Serine proteases, serpins, and neutropenia.
- Deuterium and neutrophil kinetics.
- Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy.
- Introduction to the hematopoietic growth factors.
- Cyclic and chronic neutropenia.
- Preparing for a consumer-driven genomic age.
- Cyclic neutropenia and severe congenital neutropenia in patients with a shared ELANE mutation and paternal haplotype: evidence for phenotype determination by modifying...
- Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a system...
- Recent progress in understanding the congenital neutropenias.
- Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy.
- Advances in the treatment of neutropenia.
- Granulocyte transfusion therapy: a new era?
- Genetic and molecular diagnosis of severe congenital neutropenia.
- The many causes of severe congenital neutropenia.
- Neutrophil biology and the next generation of myeloid growth factors.
- The phagocytes: neutrophils and monocytes.
- Achieving a high-performance health care system: policies and positions of the American College of Physicians.
- Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice.
- Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy.
- Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia.
- Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a system...
- Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens.
- Squatter Sam and professionalism.
- Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy.
- Updated ASCO recommendations for the use of white blood cell growth factors.
- Lineage-specific hematopoietic growth factors.
- Severe congenital neutropenia.
- The Severe Chronic Neutropenia International Registry: 10-Year Follow-up Report.
- Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients.
- Strong evidence for autosomal dominant inheritance of severe congenital neutropenia associated with ELA2 mutations.
- An adult dog with cyclic neutropenia treated by lentivirus- mediated delivery of granulocyte colony-stimulating factor.
- Update on the management of neutropenia.
- Effective storage of granulocytes collected by centrifugation leukapheresis from donors stimulated with granulocyte-colony-stimulating factor.
- Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist.
- Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose ad...
- Advances in the use of colony-stimulating factors for chemotherapy-induced neutropenia.
- Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study.
- Kostmann syndrome: severe congenital neutropenia associated with defective expression of Bcl-2, constitutive mitochondrial release of cytochrome c, and excessive apopt...
- Leukocytosis and Mobilization of CD34+ Hematopoietic Progenitor Cells by AMD3100, a CXCR4 Antagonist.
- Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management.
- Retraction. Neutrophil elastase mutations in severe congenital neutropenia patients of the original Kostmann family.
- Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices.
- Poor prognosis in elderly patients with cancer: the role of bias and undertreatment.
- Optimizing the management of chemotherapy-induced neutropenia.
- Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist.
- Treatment of canine cyclic neutropenia by lentivirus-mediated G-CSF delivery.
- Molecular basis and therapy of disorders associated with chronic neutropenia.
- Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials.
- Severe chronic neutropenia: treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry.
- Mutant elastase in pathogenesis of cyclic and severe congenital neutropenia.
- Granulocyte transfusion therapy for infections in candidates and recipients of HPC transplantation: a comparative analysis of feasibility and outcome for community don...
- Therapeutic use of cytokines to modulate phagocyte function for the treatment of infectious diseases: current status of granulocyte colony-stimulating factor, granuloc...
- Introduction: severe chronic neutropenia.
- Neutropenia: causes and consequences.
- Cyclic neutropenia.
- Alpha Omega Alpha: encouraging excellence in medicine for more than a century.
- Differential white blood cell count: underutilized or overrated.
- Inherited Neutrophil Disorders: Molecular Basis and New Therapies.
Schools
Harvard Medical School
Ma Genl Hospital
University Wa
NihNiaid
Doctors Specialties
- Internal Medicine
Accepted Insurances
- Choice Plus POS II
- Blue Card PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- First Choice Health PPO
- GEHA
- Coop Core
- Humana
- Connect
- Medicare MCR
- MultiPlan PPO
- ODS Health Plan
- Heritage Plus
- Heritage Signature
- Personal Option EPO
- Preferred Provider Network PPN
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
Awards
- Elected Member
Education
-
University of Washington -
Massachusetts General Hospital -
Harvard Medical School
Hospital
-
UW Medicine/Harborview Medical Center -
University of Washington Medical Center
Drug Facts
| NPI NUMBER | 1871633354 | |
| NPPES Provider LastName | DALE | |
| NPPES Provider FirstName | DAVID | |
| NPPES Provider ZIPCode | 981950001 | |
| NPPES Provider State | WA | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 149.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 25.0 | |
| Percent Opioid Claims | 16.78 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1871633354 |
| Last Name Of The Provider | DALE |
| First Name Of The Provider | DAVID |
| View All |
Similar Doctors
|
|
Dr. Gregory John, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David D. True, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lauren R. Thronson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bradford L. Felker, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andrew D. Graustein, MD
This Doctor is OpenDoctor Recommended.
|